Literature DB >> 26400386

Countrywide roll-out of Xpert(®) MTB/RIF in Swaziland: the first three years of implementation.

W Sikhondze1, T Dlamini2, D Khumalo3, G Maphalala4, S Dlamini4, T Zikalala5, H Albert6, J Wambugu6, K Tayler-Smith7, E Ali7, S Ade8, A D Harries9.   

Abstract

SETTING: All 19 public health laboratories in Swaziland that had Xpert(®) MTB/RIF machines installed as part of a countrywide roll-out between June 2011 and June 2014.
OBJECTIVE: To evaluate the utilisation and functionality of Xpert from 2011 to mid-2014.
DESIGN: Descriptive study of Xpert implementation using routinely collected data.
RESULTS: Of 48 829 Xpert tests conducted, 93% were successful: 14% detected Mycobacterium tuberculosis and 12% showed rifampicin resistance. The most common cause of unsuccessful tests was an 'Error' result (62%). Similar findings were obtained in government-supported and partner-supported laboratories. Annual utilisation of Xpert improved from 51% of maximum capacity in 2011 and 2012 to 74% in 2013 and 2014. A monitoring and supervision exercise of all Xpert testing sites in 2014 showed a generally good performance, with over 50% of laboratories achieving a ⩾80% score on most components. However, poor scores were obtained with equipment use and maintenance (6% achieving a score of ⩾80%), internal audit (19% achieving a score of ⩾80%) and process control (25% achieving a score of ⩾80%).
CONCLUSION: Countrywide roll-out of Xpert in Swaziland has been successful, although operational issues have been identified and need to be resolved.

Entities:  

Keywords:  SORT IT; Swaziland; Xpert® MTB/RIF; operational research; tuberculosis

Year:  2015        PMID: 26400386      PMCID: PMC4487476          DOI: 10.5588/pha.15.0001

Source DB:  PubMed          Journal:  Public Health Action        ISSN: 2220-8372


  9 in total

1.  Why ethics is indispensable for good-quality operational research.

Authors:  M Edginton; D Enarson; R Zachariah; T Reid; S Satyanarayana; K Bissell; S G Hinderaker; T Harries
Journal:  Public Health Action       Date:  2012-03-21

2.  Xpert® MTB/RIF for national tuberculosis programmes in low-income countries: when, where and how?

Authors:  A Trébucq; D A Enarson; C Y Chiang; A Van Deun; A D Harries; F Boillot; A Detjen; P I Fujiwara; S M Graham; I Monedero; I D Rusen; H L Rieder
Journal:  Int J Tuberc Lung Dis       Date:  2011-10-13       Impact factor: 2.373

3.  The Strengthening the Reporting of Observational Studies in Epidemiology (STROBE) statement: guidelines for reporting observational studies.

Authors:  Erik von Elm; Douglas G Altman; Matthias Egger; Stuart J Pocock; Peter C Gøtzsche; Jan P Vandenbroucke
Journal:  Lancet       Date:  2007-10-20       Impact factor: 79.321

4.  Feasibility, accuracy, and clinical effect of point-of-care Xpert MTB/RIF testing for tuberculosis in primary-care settings in Africa: a multicentre, randomised, controlled trial.

Authors:  Grant Theron; Lynn Zijenah; Duncan Chanda; Petra Clowes; Andrea Rachow; Maia Lesosky; Wilbert Bara; Stanley Mungofa; Madhukar Pai; Michael Hoelscher; David Dowdy; Alex Pym; Peter Mwaba; Peter Mason; Jonny Peter; Keertan Dheda
Journal:  Lancet       Date:  2013-10-28       Impact factor: 79.321

5.  Rapid molecular detection of tuberculosis and rifampin resistance.

Authors:  Catharina C Boehme; Pamela Nabeta; Doris Hillemann; Mark P Nicol; Shubhada Shenai; Fiorella Krapp; Jenny Allen; Rasim Tahirli; Robert Blakemore; Roxana Rustomjee; Ana Milovic; Martin Jones; Sean M O'Brien; David H Persing; Sabine Ruesch-Gerdes; Eduardo Gotuzzo; Camilla Rodrigues; David Alland; Mark D Perkins
Journal:  N Engl J Med       Date:  2010-09-01       Impact factor: 91.245

6.  Feasibility, diagnostic accuracy, and effectiveness of decentralised use of the Xpert MTB/RIF test for diagnosis of tuberculosis and multidrug resistance: a multicentre implementation study.

Authors:  Catharina C Boehme; Mark P Nicol; Pamela Nabeta; Joy S Michael; Eduardo Gotuzzo; Rasim Tahirli; Ma Tarcela Gler; Robert Blakemore; William Worodria; Christen Gray; Laurence Huang; Tatiana Caceres; Rafail Mehdiyev; Lawrence Raymond; Andrew Whitelaw; Kalaiselvan Sagadevan; Heather Alexander; Heidi Albert; Frank Cobelens; Helen Cox; David Alland; Mark D Perkins
Journal:  Lancet       Date:  2011-04-18       Impact factor: 79.321

7.  High prevalence of multidrug-resistant tuberculosis, Swaziland, 2009-2010.

Authors:  Elisabeth Sanchez-Padilla; Themba Dlamini; Alexandra Ascorra; Sabine Rüsch-Gerdes; Zerihun Demissie Tefera; Philippe Calain; Roberto de la Tour; Frauke Jochims; Elvira Richter; Maryline Bonnet
Journal:  Emerg Infect Dis       Date:  2012-01       Impact factor: 6.883

8.  Results from early programmatic implementation of Xpert MTB/RIF testing in nine countries.

Authors:  Jacob Creswell; Andrew J Codlin; Emmanuel Andre; Mark A Micek; Ahmed Bedru; E Jane Carter; Rajendra-Prasad Yadav; Andrei Mosneaga; Bishwa Rai; Sayera Banu; Miranda Brouwer; Lucie Blok; Suvanand Sahu; Lucica Ditiu
Journal:  BMC Infect Dis       Date:  2014-01-02       Impact factor: 3.090

9.  Impact of Xpert MTB/RIF for TB diagnosis in a primary care clinic with high TB and HIV prevalence in South Africa: a pragmatic randomised trial.

Authors:  Helen S Cox; Slindile Mbhele; Neisha Mohess; Andrew Whitelaw; Odelia Muller; Widaad Zemanay; Francesca Little; Virginia Azevedo; John Simpson; Catharina C Boehme; Mark P Nicol
Journal:  PLoS Med       Date:  2014-11-25       Impact factor: 11.069

  9 in total
  12 in total

1.  Diagnosis and treatment of TB patients with rifampicin resistance detected using Xpert(®) MTB/RIF in Zimbabwe.

Authors:  K Charambira; S Ade; A D Harries; R T Ncube; C Zishiri; C Sandy; H Mutunzi; K Takarinda; P Owiti; P Mafaune; P Chonzi
Journal:  Public Health Action       Date:  2016-06-21

2.  Impact of External Quality Assurance on the Quality of Xpert MTB/RIF Testing in Viet Nam.

Authors:  Vidyanidhi Gumma; Kyle DeGruy; Davara Bennett; Thanh Nguyen Thi Kim; Heidi Albert; Kyle B Bond; Steve Gutreuter; Heather Alexander; Lan Ngyuen Thi Phong; Thomas H Rush; Nhung Nguyen Viet; Hung Nguyen Van
Journal:  J Clin Microbiol       Date:  2019-02-27       Impact factor: 5.948

3.  Impact of Laboratory Practice Changes on the Diagnosis of Tuberculosis with the Introduction of Xpert MTB/RIF in Kiribati.

Authors:  Alfred Tonganibeia; Anthony D Harries; Onofre Edwin A Merilles; Tekaibeti Tarataake; Teatao Tiira; Takeieta Kienene
Journal:  Hawaii J Med Public Health       Date:  2018-02

4.  Has the utilisation of Xpert® MTB/RIF in Manicaland Province, Zimbabwe, improved with new guidance on whom to test?

Authors:  A Jokwiro; C Timire; A D Harries; P T Gwinji; A Mulema; K C Takarinda; P T Mafaune; C Sandy
Journal:  Public Health Action       Date:  2018-09-21

5.  The impact of the roll-out of rapid molecular diagnostic testing for tuberculosis on empirical treatment in Cape Town, South Africa.

Authors:  Sabine Hermans; Judy Caldwell; Richard Kaplan; Frank Cobelens; Robin Wood
Journal:  Bull World Health Organ       Date:  2017-04-28       Impact factor: 9.408

6.  Treatment decisions and mortality in HIV-positive presumptive smear-negative TB in the Xpert™ MTB/RIF era: a cohort study.

Authors:  Sabine M Hermans; Juliet A Babirye; Olive Mbabazi; Francis Kakooza; Robert Colebunders; Barbara Castelnuovo; Christine Sekaggya-Wiltshire; Rosalind Parkes-Ratanshi; Yukari C Manabe
Journal:  BMC Infect Dis       Date:  2017-06-16       Impact factor: 3.090

7.  Implementation of Xpert MTB/RIF in Uganda: Missed Opportunities to Improve Diagnosis of Tuberculosis.

Authors:  Colleen F Hanrahan; Priscilla Haguma; Emmanuel Ochom; Irene Kinera; Frank Cobelens; Adithya Cattamanchi; Luke Davis; Achilles Katamba; David Dowdy
Journal:  Open Forum Infect Dis       Date:  2016-05-12       Impact factor: 3.835

8.  Adherence, tolerability, and outcome after 36 months of isoniazid-preventive therapy in 2 rural clinics of Swaziland: A prospective observational feasibility study.

Authors:  Yolanda Mueller; Qhubekani Mpala; Bernhard Kerschberger; Barbara Rusch; Gugu Mchunu; Sikhathele Mazibuko; Maryline Bonnet
Journal:  Medicine (Baltimore)       Date:  2017-09       Impact factor: 1.889

9.  How has the Zimbabwe mycobacterial culture and drug sensitivity testing system among re-treatment tuberculosis patients functioned during the scale-up of the Xpert MTB/RIF assay?

Authors:  Collins Timire; Kudakwashe C Takarinda; Anthony D Harries; Herbert Mutunzi; Barbara Manyame-Murwira; Ajay M V Kumar; Charles Sandy
Journal:  Trans R Soc Trop Med Hyg       Date:  2018-06-01       Impact factor: 2.184

10.  Smear Microscopy for Diagnosis of Pulmonary Tuberculosis in Eastern Sudan.

Authors:  Yassir A Shuaib; Eltahir A G Khalil; Ulrich E Schaible; Lothar H Wieler; Mohammed A M Bakheit; Saad E Mohamed-Noor; Mohamed A Abdalla; Susanne Homolka; Sönke Andres; Doris Hillemann; Knut Lonnroth; Elvira Richter; Stefan Niemann; Katharina Kranzer
Journal:  Tuberc Res Treat       Date:  2018-06-14
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.